Search Results - "Perk, Lars R"

Refine Results
  1. 1

    Immuno‐PET: A Navigator in Monoclonal Antibody Development and Applications by van Dongen, Guus A.M.S., Visser, Gerard W.M., Lub‐de Hooge, Marjolijn N., de Vries, Elisabeth G., Perk, Lars R.

    Published in The oncologist (Dayton, Ohio) (01-12-2007)
    “…Learning Objectives After completing this course, the reader will be able to: Discuss the technical advances that have led to recent rapid developments in…”
    Get full text
    Journal Article
  2. 2

    Optimised GMP-compliant production of [18F]DPA-714 on the Trasis AllinOne module by Cybulska, Klaudia A., Bloemers, Vera, Perk, Lars R., Laverman, Peter

    Published in EJNMMI radiopharmacy and chemistry (26-05-2021)
    “…Background The translocator protein 18 kDa is recognised as an important biomarker for neuroinflammation due to its soaring expression in microglia. This…”
    Get full text
    Journal Article
  3. 3

    11C-labeled and 18F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain by Funke, Uta, Vugts, Danielle J., Janssen, Bieneke, Spaans, Arnold, Kruijer, Perry S., Lammertsma, Adriaan A., Perk, Lars R., Windhorst, Albert D.

    “…The signaling molecule histamine plays a key role in the mediation of immune reactions, in gastric secretion, and in the sensory system. In addition, it has an…”
    Get full text
    Journal Article
  4. 4

    Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p -isothiocyanatobenzyl-desferrioxamine by van Dongen, Guus A M S, Vosjan, Maria J W D, Perk, Lars R, Visser, Gerard W M, Budde, Marianne, Jurek, Paul, Kiefer, Garry E

    Published in Nature protocols (01-04-2010)
    “…The positron emitter zirconium-89 ( 89 Zr) has very attractive properties for positron emission tomography (PET) imaging of intact monoclonal antibodies (mAbs)…”
    Get full text
    Journal Article
  5. 5
  6. 6

    In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft by Nagengast, Wouter B, de Vries, Elisabeth G, Hospers, Geke A, Mulder, Nanno H, de Jong, Johan R, Hollema, Harry, Brouwers, Adrienne H, van Dongen, Guus A, Perk, Lars R, Lub-de Hooge, Marjolijn N

    Published in The Journal of nuclear medicine (1978) (01-08-2007)
    “…Vascular endothelial growth factor (VEGF), released by tumor cells, is an important growth factor in tumor angiogenesis. The humanized monoclonal antibody…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10

    Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography by Perk, Lars R, Visser, Otto J, Stigter-van Walsum, M, Vosjan, Maria J W D, Visser, Gerard W M, Zijlstra, Josée M, Huijgens, Peter C, van Dongen, Guus A M S

    “…To evaluate whether (89)Zr can be used as a PET surrogate label for quantification of (90)Y-ibritumomab tiuxetan ((90)Y-Zevalin) biodistribution and dosimetry…”
    Get full text
    Journal Article
  11. 11

    (11) C-labeled and (18) F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain by Funke, Uta, Vugts, Danielle J, Janssen, Bieneke, Spaans, Arnold, Kruijer, Perry S, Lammertsma, Adriaan A, Perk, Lars R, Windhorst, Albert D

    “…The signaling molecule histamine plays a key role in the mediation of immune reactions, in gastric secretion, and in the sensory system. In addition, it has an…”
    Get full text
    Journal Article
  12. 12

    Technical Note: Building a combined cyclotron and MRI facility: Implications for interference by Hofman, Mark B. M., Kuijer, Joost P. A., de Ridder, Jan Willem, Perk, Lars R., Verdaasdonk, Rudolf M.

    Published in Medical physics (Lancaster) (01-01-2013)
    “…Purpose: With the introduction of hybrid PET/MRI systems, it has become more likely that the cyclotron and MRI systems will be located close to each other…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging by Dijkers, Eli C.F, Kosterink, Jos G.W, Rademaker, Anna P, Perk, Lars R, van Dongen, Guus A.M.S, Bart, Joost, de Jong, Johan R, de Vries, Elisabeth G.E, Lub-de Hooge, Marjolijn N

    Published in The Journal of nuclear medicine (1978) (01-06-2009)
    “…The anti-human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is administered to patients with HER2/neu-overexpressing breast cancer…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease by Visser, Otto J, Perk, Lars R, Zijlstra, Josée M, van Dongen, Guus A M S, Huijgens, Peter C, van de Loosdrecht, Arjan A

    “…Radioimmunotherapy (RIT) is a new treatment modality that combines the benefits of radiotherapy and immunotherapy. In RIT, a radionuclide is coupled to a…”
    Get full text
    Journal Article
  18. 18

    Abstract 5275: Conjugation and radiolabeling of monoclonal antibodies and other proteins with 89Zr or 68Ga for PET imaging using p-isothiocyanatobenzyl-desferrioxamine by Vosjan, Maria Jwd, Perk, Lars R., Visser, Gerard Wm, Jurek, Paul, Kiefer, Garry E., van Dongen, Guus Ams

    Published in Cancer research (Chicago, Ill.) (15-04-2011)
    “…Presently, hundreds of intact monoclonal antibodies (mAbs) and mAb fragments are under clinical development because of their excellent potential treatment of…”
    Get full text
    Journal Article
  19. 19
  20. 20